Inhibition of CYP51A1, either pharmacologically (e.g., with ketoconazole) or genetically, reduces DCP accumulation, reprograms the immune microenvironment, and suppresses MSS CRC progression. This evidence concerns the gene CYP51A1 and colorectal carcinoma.